New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
12:46 EDTCAR, HPQ, MRK, LNKD, ZIP, UNH, SKUL, CAT, JNJOn The Fly: Midday Wrap
Stocks on Wall Street were significantly higher at midday after U.S. lawmakers agreed on a deal to avoid some of the tax hikes associated with the fiscal cliff, but many of the issues remaining were simply pushed off by the last-second agreement. The stop-gap measure puts off the drastic spending cuts that were due to take effect, but it did not eliminate them, and it failed to raise the debt limit, meaning another political showdown is coming. The day’s economic data points went largely unnoticed as most investors breathed a sigh of relief and sent the averages soaring right at the opening bell... ECONOMIC EVENTS: In the U.S., Markit's final reading for December's purchasing managers' index came in at 54.0, which was up from 52.8 a month ago and beat expectations for a downward revision to 53.6. The ISM's December manufacturing PMI had a reading of 50.7, versus the expected 50.5, while the prices paid index came in at 55.5, versus the expected 50.8. A separate report showed construction spending fell 0.3% in November, versus an expected increase of 0.6%. In Europe, Markit's zone-wide PMI edged down to 46.1 in December, compared with its 46.3 preliminary reading and down from 46.2 in November... COMPANY NEWS: Every member of the Dow Jones Industrial Average was higher at midday, with only Merck (MRK), Johnson & Johnson (JNJ) and UnitedHealth (UNH) logging gains of less than 1%. Shares of Hewlett-Packard (HPQ) and Caterpillar (CAT) paced the blue chip index, as each rose over 4%... Reflecting a trend similar to the one seen on the Dow, every S&P sector except for Healthcare was significantly higher... MAJOR MOVERS: Among the notable gainers was Zipcar (ZIP), which rose 48% following its agreement to be acquired for $12.25 per share in cash by Avis Budget (CAR), which also had its shares rise nearly 5%. Among the noteworthy losers were Skullcandy (SKUL), down 14% after Jefferies downgraded the stock to Underperform from Buy, and LinkedIn (LNKD) which fell almost 4% after being downgraded to Equal Weight at Barclays... INDICES: Near 12:30 pm ET, the Dow was up 224.78, or 1.72%, to 13,328.92; the Nasdaq was up 67.24, or 2.23%, to 3,086.75; and the S&P 500 was up 24.81, or 1.74%, to 1,451.00.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
November 19, 2015
10:26 EDTCATGoldman says sell Titan with ag and mining weakness expected to continue
Goldman Sachs downgraded Titan International (TWI) to Sell from Neutral today, saying that weakness in agriculture and mining would continue to weigh on the company's results. Goldman's downgrade comes after the company reported much weaker than expected results on November 6. Titan makes tires and wheels used in off-road vehicles which are utilized by farmers and mining and construction companies. WHAT'S NEW Titan derives 80% of its revenue from agriculture and mining, so the weakness in those sectors will continue to hurt its results going forward, wrote Goldman analyst David Tamberino. Additionally, farmers have less money to spend on capital projects, reducing the likelihood that they will adopt Titan's new LSW tires, according to the analyst. Given these factors and the January 2017 maturity of Titan's convertible note, the company could be faced with a cash crunch, the analyst warned. Moreover, Titan is facing increased competition, according to Tamberino. He sharply lowered his 2015-2017 earnings before interest, taxes, depreciation and amortization estimates for the company and slashed his price target on the name to $3 from $8. WHAT'S NOTABLE: Deere (DE), Caterpillar (CAT), and AGCO (AGCO) sell heavy machinery used in agriculture. PRICE ACTION: In early trading, Titan sank 11% to $4.50.
10:23 EDTUNHUnitedHealth selloff on guidance presents buying opportunity, says Leerink
Subscribe for More Information
10:00 EDTUNHUnitedHealth pulls back on marketing efforts for individual exchange programs
UnitedHealthcare announced it has pulled back on its marketing efforts for individual exchange products in 2016. The company is evaluating the viability of the insurance exchange product segment and will determine during the first half of 2016 to what extent it can continue to serve the public exchange markets in 2017.
09:16 EDTUNHUnitedHealth falls on FY15 guidance
Subscribe for More Information
09:00 EDTHPQAerohive sell-off unwarranted, says JMP Securities
Subscribe for More Information
07:46 EDTUNHOptions expected to be active; UNH AET ANTM CI WCG HUM HNT CNC
Subscribe for More Information
06:40 EDTUNHUnitedHealth volatility flat into lowering FY15 guidance
Subscribe for More Information
06:34 EDTMRKEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
06:11 EDTUNHUnitedHealth to host conference call
Subscribe for More Information
05:59 EDTUNHUnitedHealth cuts FY15 to $6.00 from $6.25-$6.35
Subscribe for More Information
05:57 EDTUNHUnitedHealth sees FY16 EPS $7.10-$7.30, consensus $7.28
Subscribe for More Information
November 18, 2015
15:40 EDTUNHCongressman says U.S. may need look at pharmacy competition, dealReporter says
Subscribe for More Information
08:11 EDTMRK, JNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
08:01 EDTSKULFurey Research Partners to hold a conference
Hidden Gems Conference is being held in New York on November 18.
07:57 EDTCARBarclays to hold a conference
Subscribe for More Information
07:01 EDTMRKThreshold enters into definitive co-promotion agreement with Merck
Threshold Pharmaceuticals (THLD) announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck (MRK) pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015. Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440M.
November 17, 2015
09:05 EDTUNHOptumRx acquires AxelaCare
Subscribe for More Information
08:04 EDTMRKMerck to present new KEYTRUDA findings at upcoming congresses
Merck announced that data investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, in advanced non-small cell lung cancer, melanoma, classical Hodgkin lymphoma, multiple myeloma, and ER-positive/HER2-negative breast cancer will be presented at four medical congresses through the end of this year. In total, data from more than 30 abstracts will be presented at the Society for Melanoma Research 2015 Congress in San Francisco, Nov. 18 - 21; the 57th American Society of Hematology Annual Meeting in Orlando, Florida, Dec. 5 - 8; the San Antonio Breast Cancer Symposium, Dec. 8 - 12; and the European Society for Medical Oncology Asia 2015 Congress in Singapore, Dec. 18 - 21. By the end of 2015, data on the anti-tumor activity of KEYTRUDA will have been presented across more than 20 tumor types. "The field of immuno-oncology holds great potential across a broad spectrum of cancers," said Dr. Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories. "Data for KEYTRUDA being presented at these scientific meetings include a first-time comparison to chemotherapy in advanced non-small cell lung cancer, novel combination data in advanced melanoma as well as first-time data in two additional tumor types, namely multiple myeloma and hormone receptor positive breast cancer, further demonstrating our deep commitment to advancing cancer treatment."
07:56 EDTLNKDUBS to hold a conference
Global Technology Conference is being held in San Francisco on November 16-18 with webcasted company presentations to begin on November 17 at 10:45 am.; not all company presentations may be webcasted. Webcast Link
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use